Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB:TRUFF) highlighted an FDA IND–authorized Phase 1 study led at the University of Washington showing that a second psilocybin session produced sustained psychological benefits in metastatic cancer patients.
Key data: mean HADS fell from 15.08 to 9.00 after the second session, 69% of participants dropped below clinical anxiety/depression thresholds, and reports of complete mystical experience rose from 38% to 77%. No serious adverse events reported. Filament's PEX010 now supplied to 70+ clinical sites worldwide. Red Light is promoting this evidence amid its proposed acquisition of Filament and evolving U.S. policy support for psychedelic research.
Red Light Holland (OTCQB:TRUFF) reported that Filament Health signed three new license agreements and completed two research shipments in March 2026, expanding PEX010 clinical research across Australia, the United Kingdom and Canada.
The company disclosed a definitive arrangement to acquire Filament, an interim Supreme Court of British Columbia order on March 23, 2026, and that PEX010 has clinical trial authorizations from Health Canada, the U.S. FDA and 10 other jurisdictions.
Red Light Holland (OTCQB: TRUFF) said it will support UCSF's Carhart-Harris Lab Global Psychedelic Study by directing researchers and clinicians receiving Filament Health's psilocybin candidate PEX010 on how to join the large-scale online study.
Filament has supplied PEX010 to over 70 trials worldwide and is authorized for use in several federally authorized compassionate use programs.
Red Light Holland (OTCQB: TRUFF) and Filament Health (OTC: FLHLF) received an Interim Order from the Supreme Court of British Columbia advancing Red Light's proposed statutory plan of arrangement to acquire Filament.
The order authorizes a Filament shareholder meeting on April 24, 2026; Filament's board unanimously recommends approval. Filament shareholders of record on March 2, 2026 may vote. Completion remains subject to shareholder, court and regulatory approvals.
Red Light Holland (OTCQB:TRUFF) engaged Kala Bio's Researgency.ai to support clinical development of Filament Health's patented botanical psilocybin candidate PEX010.
The company announced a definitive arrangement to acquire Filament's business, including 76 issued patents across 15 families, noted PEX010 has Health Canada and FDA trial authorizations, positive Phase 2 data in alcohol use disorder, and supply to >70 clinical sites.
Red Light Holland (OTCQB: TRUFF) will acquire Filament Health via a statutory plan of arrangement, combining Filament's GMP manufacturing, Health Canada Dealer's Licence, FDA‑authorized clinical programs and 76 issued patents with Red Light's mass cultivation, brand presence and microdosing data.
The all‑share deal issues up to 182,447,452 consideration shares, leaves existing Red Light holders with ~70% post‑closing, and targets closing in Q2 2026 subject to approvals.
Red Light Holland (OTCQB: TRUFF) will acquire Filament Health by plan of arrangement to combine GMP pharmaceutical manufacturing, a Health Canada Level 8 Dealer's Licence, an FDA-authorized clinical program and 76 issued patents covering natural psilocybin technologies.
The all-share transaction issues up to 182,447,452 Consideration Shares, leaves existing Red Light shareholders with ~70% ownership post-close, and targets completion in Q2 2026.
Red Light Holland (OTCQB: TRUFF) reported Q3 2026 results for the three and nine months ended December 31, 2025, with total cash of $9.238M and revenue of $1.265M for the quarter (up 8.3% year-over-year). Gross profit fell to $0.358M (down 13.7% YoY) while G&A expenses declined 15.8%. The company ceased shiitake production at AEM and is pursuing strategic R&D, M&A evaluations, and distribution growth, including Netherlands truffle sales to over 125 retailers and expanded U.S. retail activity with Albertsons/Safeway.
Red Light Holland (OTCQB:TRUFF) reported Q2 2026 results and a corporate update for the quarter ended September 30, 2025. Key metrics: Revenue $0.754M (down 44.9% YoY), Gross profit $0.327M (down 68.7% YoY), Adjusted EBITDA loss $0.785M (worse 61.9% YoY), Cash $10.226M, Total assets $19.018M.
Operational highlights include expanded U.S. retail distribution with Albertsons/Safeway, new R&D milestones with DEA-registered Irvine Labs (5kg shipment; potency testing compatible with manufacturing), ASU collaboration, and appointment of Dr. Robin Carhart-Harris as scientific advisor. Company pursuing M&A, streamlining, and a Bitcoin allocation up to $2M.
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs in California received a second, larger 5 kg shipment of naturally occurring psilocybin imported under a United States Controlled Substances import permit on November 19, 2025.
The shipment was processed under Irvine Labs' 2025 DEA quota after potency testing and process validation confirmed compatibility with medical‑grade manufacturing. The companies said this scale‑up will support expanded R&D toward standardized psilocybin products and clinical/therapeutic programs. The company also issued 3,250,719 common shares at a deemed price of $0.035 per share to arm's length creditors.